Last edition
News about "AstraZeneca?s ELEVATE-RR phase III trial of Calque"
Final results from the head-to-head ELEVATE-RR phase III trial of AstraZeneca's Calquence (acalabrutinib) demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in adults with previously treated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia
AstraZeneca?s ELEVATE-RR Phase III Trial Of Calque | 08/06/2021 | By Darshana | 518
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members